| Third-line Sorafenib after sequential therapy with Sunitinib and mTOR ... - UroToday |
|
|
UroTodaySunitinib and everolimus have been approved for first- and second-line treatment, respectively, in metastatic renal cell carcinoma (mRCC). ... read more |